{"id":"https://openalex.org/W3083384656","doi":"https://doi.org/10.1158/1538-7445.am2020-3407","title":"Abstract 3407: Anti-tumor activity of tepotinib in orthotopic models of lung cancer patient-derived brain metastases with MET amplification","display_name":"Abstract 3407: Anti-tumor activity of tepotinib in orthotopic models of lung cancer patient-derived brain metastases with MET amplification","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083384656","doi":"https://doi.org/10.1158/1538-7445.am2020-3407","mag":"3083384656"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-3407","doi":"https://doi.org/10.1158/1538-7445.am2020-3407","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-3407","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036477513","display_name":"Manja Friese\u2010Hamim","orcid":"https://orcid.org/0009-0008-8208-8478","observed_orcids":["https://orcid.org/0009-0008-8208-8478"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Manja Friese-Hamim","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065197387","display_name":"Anderson Clark","orcid":"https://orcid.org/0009-0004-4246-5874","observed_orcids":["https://orcid.org/0009-0004-4246-5874"]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Anderson Clark","raw_affiliation_strings":["2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069779817","display_name":"Lindsey Crowley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Lindsey Crowley","raw_affiliation_strings":["2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054495303","display_name":"Christof Reusch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christof Reusch","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086810432","display_name":"Olga Bogatyrova","orcid":"https://orcid.org/0009-0009-9346-3795","observed_orcids":["https://orcid.org/0009-0009-9346-3795"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Olga Bogatyrova","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036553821","display_name":"Claudia Wilm","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Claudia Wilm","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100430287","display_name":"Hong Zhang","orcid":"https://orcid.org/0000-0002-4084-5150","observed_orcids":["https://orcid.org/0000-0002-4084-5150","https://orcid.org/0000-0002-7544-0786"]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hong Zhang","raw_affiliation_strings":["2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052666612","display_name":"Timothy Crandall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Timothy Crandall","raw_affiliation_strings":["2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101816381","display_name":"Jing Lin","orcid":"https://orcid.org/0000-0002-4199-3980","observed_orcids":["https://orcid.org/0000-0002-4199-3980"]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jing Lin","raw_affiliation_strings":["2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100962170","display_name":"Jianguo Ma","orcid":"https://orcid.org/0009-0007-5184-7550","observed_orcids":["https://orcid.org/0009-0007-5184-7550"]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jianguo Ma","raw_affiliation_strings":["2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Translational Innovation Platform, Oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA;","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082999862","display_name":"David Bachner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Bachner","raw_affiliation_strings":["3EMD Serono Research & Development Institute, Inc., Billerica, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3EMD Serono Research & Development Institute, Inc., Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049067659","display_name":"J\u00fcrgen Schmidt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"J\u00fcrgen Schmidt","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Martin Schaefer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin Schaefer","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021088641","display_name":"Christopher Stroh","orcid":"https://orcid.org/0009-0002-2635-4176","observed_orcids":["https://orcid.org/0009-0002-2635-4176"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christopher Stroh","raw_affiliation_strings":["1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany;","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"3407","last_page":"3407"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tepotinib","display_name":"tepotinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/met-amplification","display_name":"MET amplification","score":0.9229999780654907},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8309999704360962},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.9810000061988831},{"id":"https://openalex.org/keywords/met-inhibitors","display_name":"MET inhibitors","score":0.9909999966621399},{"id":"https://openalex.org/keywords/capmatinib","display_name":"capmatinib","score":0.824999988079071},{"id":"https://openalex.org/keywords/savolitinib","display_name":"savolitinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":1.0},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.9290000200271606},{"id":"https://openalex.org/keywords/brain-penetration","display_name":"brain penetration","score":0.45100000500679016},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6980000138282776},{"id":"https://openalex.org/keywords/met-exon-14-skipping","display_name":"MET exon 14 skipping","score":0.8220000267028809},{"id":"https://openalex.org/keywords/gene-copy-number","display_name":"gene copy number","score":0.6110000014305115}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9237509369850159},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8147791624069214},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6969726085662842},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4955085515975952},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45407095551490784},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4475288987159729},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3921997547149658},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34915685653686523},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-3407","doi":"https://doi.org/10.1158/1538-7445.am2020-3407","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-3407","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4200150838","https://openalex.org/W3120378149","https://openalex.org/W3088486824","https://openalex.org/W4379983537","https://openalex.org/W3127624579","https://openalex.org/W4286512385","https://openalex.org/W3138176389","https://openalex.org/W3166914169","https://openalex.org/W4362454845","https://openalex.org/W4415939839"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Patients":[2],"with":[3,39,95,172,201,250,293,312,336,367,408,463],"advanced":[4,40],"non-small":[5],"cell":[6],"lung":[7,122,458],"cancer":[8,123,459],"(NSCLC)":[9],"harboring":[10],"oncogenic":[11],"MET":[12,16,21,27,84,162,202,270,275,314,464],"alterations,":[13],"such":[14],"as":[15],"exon":[17],"14":[18],"skipping":[19],"or":[20,174,217,338],"amplification":[22,465],"(MET":[23],"amp),":[24],"benefit":[25],"from":[26,100],"tyrosine":[28],"kinase":[29],"inhibitor":[30],"(TKI)":[31],"treatment.":[32,237],"Brain":[33],"metastases":[34,130,376,394,462],"are":[35],"common":[36],"in":[37,45,63,71,91,116,132,168,233,274,300,372,388,454],"patients":[38,407],"NSCLC.":[41],"In":[42,75,330],"preclinical":[43],"studies":[44],"rats,":[46],"tepotinib":[47,61,110,175,205,236,350,453],"had":[48,269],"relatively":[49],"high":[50],"binding":[51],"to":[52,160,235,341,380,406],"brain":[53,64,103,129,375,393,409,461],"tissue":[54],"(fu":[55],"br=0.4%,":[56],"fu":[57],"pl=4%)":[58],"and":[59,89,150,190,230,295,346,351,358,369,402,414,484],"free":[60],"concentrations":[62,69],"were":[65,140,164,182,199,257],"25%":[66],"of":[67,82,109,119,128,137,187,224,261,277,287,306,365,452,457,469,473],"the":[68,80,83,258,262,331,373,382,389,470,474],"found":[70,159],"plasma":[72],"(Kp":[73],"u,u=0.25).":[74],"this":[76],"study":[77],"we":[78],"investigated":[79,115,265],"efficacy":[81,413],"TKIs":[85,203,315],"tepotinib,":[86,322],"capmatinib,":[87,324],"savolitinib":[88,213,339],"crizotinib":[90,218,337],"mice":[92,134,170,189],"implanted":[93,184,239,284,302],"orthotopically":[94,183,282],"MET-dependent":[96],"tumor":[97,191,318,354,400],"explants":[98],"derived":[99],"human":[101],"NSCLC":[102],"metastases.":[104,410],"Methods":[105],"The":[106,362],"antitumor":[107],"activity":[108,451],"(30":[111,210],"mg/kg":[112,177,207,211,215,220],"qd)":[113,216],"was":[114,193,310,386],"a":[117],"screen":[118],"21":[120,225],"subcutaneous":[121,226],"patient-derived":[124,460],"xenograft":[125],"(PDX)":[126],"models":[127,181,245,264,280,377,456],"grown":[131],"NOD-SCID":[133,169,188],"(n=1/model).":[135],"20":[136,263],"these":[138,256],"tumors":[139,198,228,260,309,396],"retrospectively":[141],"analyzed":[142],"for":[143,477],"cancer-specific":[144],"mutations,":[145],"gene":[146,151],"copy":[147],"number":[148],"(GCN)":[149],"expression":[152],"by":[153,195,266,398],"Nanostring.":[154],"2":[155,223],"responding":[156],"models,":[157],"both":[158,244],"harbor":[161],"amp,":[163],"tested":[165],"again":[166,241],"subcutaneously":[167,240],"treated":[171,200],"vehicle":[173],"(125":[176,206],"qd;":[178],"n=5).":[179],"Both":[180,279],"into":[185,242,285],"brains":[186,286],"growth":[192,342],"monitored":[194],"MRI.":[196],"Established":[197],"(n=10)":[204],"qd),":[208],"capmatinib":[209,352],"bid),":[212],"(60":[214],"(50":[219],"qd).":[221],"Results":[222],"PDX":[227,395],"(LU5406":[229],"LU5349)":[231],"regressed":[232,246],"response":[234],"When":[238],"mice,":[243],"completely":[247],"upon":[248],"treatment":[249,335],"tepotinib.":[251],"Molecular":[252],"profiles":[253],"revealed":[254],"that":[255,268],"only":[259],"Nanostring":[267],"amp":[271],"(high-level":[272],"increase":[273],"GCN":[276],">10).":[278],"grew":[281],"when":[283],"mice.":[288],"Contrast-weighted":[289],"MRI":[290],"indicated":[291],"regions":[292,366],"intact":[294,368],"disrupted":[296,370],"blood\u2013brain":[297],"barrier":[298],"(BBB)":[299],"all":[301,313],"tumors.":[303],"Tumor":[304],"regression":[305,355,401],"orthotopic":[307,332,374,392,455],"LU5406":[308],"observed":[311],"(%":[316],"median":[317],"volume":[319],"changes":[320],"[%TV]:":[321],"\u201363%;":[323],"\u201324%;":[325],"savolitinib,":[326],"\u201338%;":[327],"crizotinib,":[328],"\u201327%).":[329],"LU5349":[333],"tumors,":[334],"led":[340],"inhibition":[343],"(%TV:":[344,356],"+88%":[345],"\u201313%,":[347],"respectively),":[348],"whereas":[349],"induced":[353],"\u201384%":[357],"\u201363%,":[359],"respectively).":[360],"Conclusions":[361],"heterogenous":[363],"pattern":[364],"BBB":[371,415],"is":[378],"thought":[379],"mirror":[381],"clinical":[383],"situation.":[384],"Tepotinib":[385],"efficacious":[387],"two":[390],"MET-driven":[391],"characterized":[397],"pronounced":[399],"may":[403],"be":[404,418],"relevant":[405],"Relationships":[411],"between":[412],"leakiness":[416],"will":[417],"discussed.":[419],"Citation":[420],"Format:":[421],"Manja":[422],"Friese-Hamim,":[423],"Anderson":[424],"Clark,":[425],"Lindsey":[426],"Crowley,":[427],"Christof":[428],"Reusch,":[429],"Olga":[430],"Bogatyrova,":[431],"Claudia":[432],"Wilm,":[433],"Hong":[434],"Zhang,":[435],"Timothy":[436],"Crandall,":[437],"Jing":[438],"Lin,":[439],"Jianguo":[440],"Ma,":[441],"David":[442],"Bachner,":[443],"J\u00fcrgen":[444],"Schmidt,":[445],"Martin":[446],"Schaefer,":[447],"Christopher":[448],"Stroh.":[449],"Anti-tumor":[450],"[abstract].":[466],"In:":[467],"Proceedings":[468],"Annual":[471],"Meeting":[472],"American":[475],"Association":[476],"Cancer":[478,490],"Research":[479],"2020;":[480],"2020":[481],"Apr":[482],"27-28":[483],"Jun":[485],"22-24.":[486],"Philadelphia":[487],"(PA):":[488],"AACR;":[489],"Res":[491],"2020;80(16":[492],"Suppl):Abstract":[493],"nr":[494],"3407.":[495]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2020-09-11T00:00:00"}